Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

March 15th 2023

Moshe Ornstein, MD, MA, starts a conversation on how patients with metastatic renal cell carcinoma are classified by risk, and how risk category influences approaches to systemic therapy.

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

March 10th 2023

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

The combination of cabozantinib and atezolizumab elicited responses in patients with non–clear cell renal cell carcinoma, according to extended follow-up data from the phase 1b COSMIC-021 trial.

PFS Benefit With Frontline Nivolumab/Cabozantinib Vs Sunitinib Is Independent of PD-L1 or c-MET Status in Advanced RCC

March 9th 2023

The progression-free survival benefit associated with the combination of nivolumab plus cabozantinib compared with sunitinib was largely independent of PD-L1 and c-MET status in previously untreated patients with advanced or metastatic renal cell carcinoma.

Dr. Galsky on the Rationale for the CheckMate-274 Trial in Urothelial Cancer

March 8th 2023

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate-274 trial in patients with urothelial cancer.

FDA Grants Fast Track Designation to IK-175 in Combination With Nivolumab in Urothelial Carcinoma

March 8th 2023

The FDA has granted a fast track designation to the novel aryl hydrocarbon receptor antagonist IK-175 in combination with nivolumab for the treatment of patients with advanced urothelial carcinoma who have progressed on or within 3 months of receiving the last dose of checkpoint inhibitors.

Making Pancreatic Cancer Treatments More Effective

March 8th 2023

Pancreatic cancer diagnoses are increasing more rapidly than any other cancer type while remaining one of the most deadly cancers.

Cabozantinib Plus Atezolizumab Misses PFS End Point in Previously Treated Advanced RCC

March 7th 2023

The combination of cabozantinib and atezolizumab did not significantly improve progression-free survival over cabozantinib alone in patients with locally advanced or metastatic clear cell or non–clear cell renal cell carcinoma who progressed during or following checkpoint inhibition, missing the primary end point of the phase 3 CONTACT-03 trial.

Dr. Chatzkel on the Rationale for the IMMCO-1 trial in mCRPC and Other Immunologically Cold Tumors

March 1st 2023

Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.

Dr. Braun on the Role of SLAMF7+ CD8+ T-cells in Nivolumab-Resistant RCC

March 1st 2023

David A. Braun, MD, PhD, discusses the enrichment of SLAMF7-positive, CD8-positive T-cells and their role on nivolumab resistance in clear cell and non–clear cell renal cell carcinoma.

FDA Approval Sought for Niraparib Plus Abiraterone/Prednisone as First-line Treatment for BRCA+ mCRPC

March 1st 2023

A new drug application has been submitted to the FDA seeking the approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet, and prednisone, for the first-line treatment of patients with metastatic castration-resistant prostate cancer harboring BRCA mutations.

Savolitinib Plus Durvalumab Produces Responses, Tolerability in MET-Driven Papillary Renal Cancer Subset

March 1st 2023

The combination of savolitinib and durvalumab induced high response rates with a manageable safety profile in patients with metastatic papillary renal cancer with MET-driven disease enrolled to the phase 2 CALYPSO trial, although the trial missed its primary end point of confirmed response rate for the overall study population.

Dr. Nguyen on Primary Analysis of the FORMULA-509 Trial in Prostate Cancer

February 28th 2023

Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.

Dr. Sonpavde on Predicting 5-year Survival Outcomes in MIBC Using Neural Network Analysis

February 28th 2023

Guru P. Sonpavde, MD, discusses the methodology and key results from an analysis of the Cancer Genome Atlas in muscle-invasive bladder cancer.

AR Pathway Inhibitors, ADCs, and IO/TKI Combinations Shape Standard Therapy in GU Cancers

February 24th 2023

Chandler Park, MD, MSc, FACP, discusses the evolution of metastatic hormone-sensitive prostate cancer treatment, shifting definitions of metastatic and nonmetastatic castration-resistant prostate cancer, the importance of antibody-drug conjugates in bladder cancer, and the future of biomarkers in renal cell carcinoma.

Investigational Treatments for Refractory RCC Expand Beyond Immunotherapy

February 23rd 2023

Brian I. Rini, MD, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy; the potential role of biomarkers in future targeted treatments; and the need for novel mechanisms such as HIF inhibition to meet the needs of patients who don’t respond to immunotherapy or VEGF TKIs.

Dr. Daneshmand on Erdafitinib in NMIBC

February 22nd 2023

Siamak Daneshmand, MD, discusses findings from the interim analysis of cohort 3 of the multicohort phase 2 THOR-2 trial.

Dr. Efstathiou on Niraparib Plus Abiraterone Acetate in mCRPC

February 22nd 2023

Eleni Efstathiou, MD, PhD, discusses second interim findings from a subgroup analysis of the phase 3 MAGNITUDE trial in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Dr. Atkins on TFS Outcomes from the HCRN GU16-260 Trial in RCC

February 22nd 2023

Michael B. Atkins, MD, discusses the treatment-free survival outcomes from cohort A of the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.